We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
01/12/2015 13:30 | Financially, Collagen Solutions made a big leap with revenues up more than ten-fold year on year at £1.46mln in the six months to September 30. The underlying loss (LBITDA) of £79,376 reveals the group is approaching break-even. The figure has narrowed from over £522,000 previously. The loss before tax was also down sharply at £356,537. Importantly, the business still in a very healthy position with £3.1mln in the bank. | jacobjohn7 | |
01/12/2015 13:28 | Collagen Solutions' interims chart a period of significant progress Share 08:02 01 Dec 2015 The company is is making headway both operationally and financially. Collagen Solutions' interims chart a period of significant progress Recent acquisition ChondroMimetic provides collagen-based implant for treatment of small cartilage and underlying bone defects. Collagen Solutions (LON:COS) interims revealed it is making headway both operationally and financially. The company expanded its expertise in September with the acquisition of ChondroMimetic, which provides collagen-based implant for treatment of small cartilage and underlying bone defects. It also strengthened the board with the appointment of chief operating officer Tom Hyland and secured a significant supply deal with Histogenics Corp during the period under review. Other highlights included the granting of a patent for processing new biomaterial for heart patients, while its experts also joined teams carrying out pioneering work in arthritis and Parkinson’s disease. Financially, Collagen Solutions made a big leap with revenues up more than ten-fold year on year at £1.46mln in the six months to September 30. The underlying loss (LBITDA) of £79,376 reveals the group is approaching break-even. The figure has narrowed from over £522,000 previously. The loss before tax was also down sharply at £356,537. Importantly, the business still in a very healthy position with £3.1mln in the bank. Chief executive Stewart White told investors: “The Collagen Solutions value proposition received further external validation within the period via supply agreements signed with new customers, additional FDA approval of customers' products and our participation in cutting edge research programmes in new clinical areas such as the treatment for Parkinson's disease. “These achievements have been possible through the hard work of our colleagues across the globe." | jacobjohn7 | |
01/12/2015 12:31 | done dummy sell for decent qty and the market makers certainly want shares... good sign | jacobjohn7 | |
01/12/2015 12:27 | Having read that growth is very impressive at this stage and well within forecasts and should be headlined by financial media tomorrow. Cash balance is impressive, and opportunities are growing. I'm happy with it, and content to let the story unfold, another contract win RNS would get us bouncing along merrily though. Building an facility extension for a specific company is very exciting, as well as building production capacity for the future it makes you think how big a company and revenue potential they are doing this for. This is as good as could have been expected at this stage... and the forecast of cash flow positivity by end of the year would be very impressive... IMO this will snowball quite quickly once we gain that traction. | jacobjohn7 | |
01/12/2015 12:12 | -- Revenue and other income increased to GBP1,460,218 (H1 2014: GBP143,213) | jacobjohn7 | |
01/12/2015 12:05 | Collagen Solutions PLC 01 December 2015 1 December 2015 Collagen Solutions Plc (the "Company" or the "Group") Half Yearly Report Interim Results for the six months ended 30 September 2015 Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces results for the six months ended 30 September 2015. Financial Highlights -- Revenue and other income increased to GBP1,460,218 (H1 2014: GBP143,213) -- LBITDA- GBP(79,376) (H1 2014: GBP(522,144) -- Pre-tax loss - GBP(356,537) (H1 2014: GBP(560,831) -- Basic loss per share - (0.26)p (H1 2014: (0.88)p) -- Net cash balances of GBP3,104,230 at 30 September 2015 (31 March 2015 : GBP3,391,356) Operational Highlights -- Acquisition of assets and exclusive world licence for ChondroMimetic, a collagen based implant for treatment of small osteochondral (cartilage and underlying bone) defects, together with related IP for use in other clinical applications. -- Management team strengthened by appointment of Chief Operating Officer -- Supply agreement signed with Histogenics Corporation -- New US patent granted for processing of new biomaterial for heart patients -- Partnership with UCL and Oxford MEStar in grant award from Arthritis Research UK -- Joined EUR4 million Horizon 2020 grant funded research project to develop novel treatments for Parkinson's disease Post Period End -- R&D headcount increased in San Jose to further develop new high value collagen products -- Management team strengthened by appointment of Chief Business Officer in USA Dr Stewart White, Chief Executive Officer of Collagen Solutions, commented: "I am pleased to report that trading for the period demonstrated a significant increase in revenue with reduction in LBITDA compared with the same period in 2014, whilst maintaining a healthy cash position. The Collagen Solutions value proposition received further external validation within the period via supply agreements signed with new customers, additional FDA approval of customers' products and our participation in cutting edge research programmes in new clinical areas such as the treatment for Parkinson's disease. These achievements have been possible through the hard work of our colleagues across the globe." Collagen Solutions Plc David Evans, Chairman Tel: 07740 084 452 Stewart White, CEO / Tel: 0141 648 9100 Gill Black, CFO Panmure Gordon (Nominated Adviser and Broker) Rob Naylor (Corporate Finance) Tel: 0207 886 2714 Maisie Atkinson (Corporate Tel: 0207 886 2905 Sales) Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr. Mike Wort Mob: 07900 608 002 Anna Dunphy Mob: 07876 741 001 Chairman's Statement I am pleased to present Collagen Solutions' interim results for the six month period ended 30 September 2015. During the period, we have made further progress in increasing revenue from new and existing customers and products across the Group. The strategic objective is to build a significant global biomaterials business by assisting customers in expediting the transition of their products from development through to manufacture by the provision of cost effective, functional medical grade collagen materials and devices across a range of clinical indications, for the ultimate benefit of patients by providing effective and affordable treatments. Overview During this six month period, revenue has increased by 141% over the full year revenue for 2014/15. Revenue growth has come from both our material supply and contract manufacturing activities with the acquisition of Southern Lights Biomaterials making a significant contribution. We have continued to invest in our R&D teams, senior management team, internally generated IP; such as the new US patent granted in May, and our manufacturing facilities in the UK and New Zealand. We have also taken the opportunity to acquire the assets and exclusive worldwide IP licence to the ChondroMimetic product, a collagen based implant for treatment of cartilage and underlying bone defects. This IP family and platform technology also gives opportunities to develop a pipeline of additional products from the platform technologies for further clinical indications which we believe have the potential to create long-term shareholder value. The senior management teams in Glasgow, San Jose and New Zealand have been successfully integrated and are working effectively as a cohesive unit to execute our strategic plan. We have set ourselves a target by 2020 to create a biomaterials business with a value of GBP100 million, through a combination of organic growth, exploitation of licensed IP and appropriate acquisitions. In order to achieve this we have been putting in place the necessary resources to make this happen. Results The Group's results for the six months ended 30 September 2015 are set out in the Consolidated Statement of Comprehensive Income. Revenue (including other income) for the first six months was up significantly to GBP1,460,218 (2014: GBP143,213). Administrative expenses were GBP898,284 (2014: GBP467,672), selling and marketing costs were GBP266,300 (2014: GBP161,171), LBITDA for the first six months was (GBP79,376) (2014: (GBP522,144)), and the loss per share reduced to (0.26)p (2014: (0.88)p). Net cash generated from operations during the period was GBP35,444. The Group's cash balances at 30 September 2015 were GBP3,104,230 (31 March 2015: GBP3,391,356). Board and management The team is working together well as a cohesive unit under Stewart's leadership, with the Scientific Advisory Board providing important input into our product development strategies through the stage gate process. At the start of the period, we appointed Tom Hyland as Chief Operating Officer. Tom has a wealth of knowledge and experience in collagen chemistry and GMP manufacturing. More recently we are delighted to welcome Jamal Rushdy as Chief Business Officer. He has over 20 years' experience in the medical device arena, specifically within two mid-size high growth public companies and three successful start-ups. Jamal has an impressive track record of building businesses with successful exits and transforming organisations through integration and performance improvement. The Board and the employees of Collagen Solutions are deeply saddened by the recent death, after a short illness, of our Non-Executive Director, Dr Kevin Wilson. Kevin was both a close friend and colleague of mine of many years standing and he played a pivotal role in the formation of this Company. His humanity, wit, creativity and enthusiasm will be sadly missed. He never sought the limelight and I often felt he never got the credit he deserved from others outside his close circle of friends. Kevin's passing leaves a gap in our Board that will be enormously difficult to fill and we will update you in due course in this regard. As a consequence of this, I will be assuming the role of Chairman of the Audit and Risk Committee. Current Outlook As I look forward in terms of the rest of this financial year and beyond I am encouraged by our continued progress and the overall direction of travel. As ever my desire for greater momentum and being able to execute the opportunities we have in a timely fashion remains a high priority. The overall positive background and the ability to secure new contracts gives me comfort that the second half of the year will see further growth in our revenues. Our pipeline of opportunities continues to remain robust but with a degree of uncertainty prevailing regarding the exact timing of contract execution. We have yet to reach a critical mass of manufactured product and consistent cash flow positivity. We anticipate, excluding investing activities we will be operationally cash positive by the year end, if not for the year as a whole. There are a number of more significant growth opportunities which may crystallise in 2016; - The building of a new facility in New Zealand to accommodate a specific customer requirement; - The establishment of a joint-venture in China in order to work in the Chinese market with the right partner so that our products can service particular market segments cost effectively; and - The commercialisation of the IP from ChondroMimetic, a treasure trove of value enhancing opportunities. This however will require its own dedicated management team if we are to retain our focus in our core business. We continue to build our Company and its infrastructure in a relatively low risk manner by adopting a portfolio approach in a multi-product/custom Thank you for your support David E Evans Chairman 1 December 2015 Collagen Solutions Plc CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (MORE TO FOLLOW) Dow Jones Newswires December 01, 2015 02:00 ET (07:00 GMT) For the six months ended 30 September 2015 | jacobjohn7 | |
01/12/2015 12:04 | FLASH: Collagen Solutions losses narrow 1 December 2015 | 07:26am StockMarketWire.com - - See more at: hxxp://www.stockmark | jacobjohn7 | |
01/12/2015 09:50 | Building a new facility in N.Z. and adding to the existing management team will mean more expenditure. Meanwhile the long term chart in the header doesn't paint a very good picture and it's all very well the company saying their objective is to make this into a £100 million company by 2020, but existing long term shareholders, like myself, may be thinking they would be better off having their money in a bank account earning zero interest. imo | doodlebug4 | |
01/12/2015 08:04 | I rather like the tone and realism in the Chairman's statement, but there is clearly a big opportunity for this company. Cashflow breakeven by year end would be excellent. I do wonder whether the new facility in NZ, if needed, will require an additional fund raising in due course. | 18bt | |
30/11/2015 13:29 | Half year results tomorrow jacobjohn, so we will soon find out the answer to that. | doodlebug4 | |
26/11/2015 10:28 | Am i right in my thinking that the late payments that didnt make it onto previous results will appear on the interims 2nd December. .. and thus more chance of over achieving ☺ | jacobjohn7 | |
20/11/2015 15:33 | RIP, Kevin Wilson | doodlebug4 | |
20/11/2015 11:42 | quite right.. been trading between 8-13p range up and down think this will be one of the best buying/adding points in last year... Added £4k yesterday have a bit more dry powder but want momentum upwards now... | jacobjohn7 | |
20/11/2015 11:39 | The markets like a 'bargain' and so do the shareholders.:-) | doodlebug4 | |
20/11/2015 11:25 | Interesting article that.. the markets always like a 'bargain' and not overpaying for acquisitions... and so does the bottom line... ;o) | jacobjohn7 | |
18/11/2015 15:24 | Positive noises and revenue streams building up... but have to remember the fact that the company is forward thinking aquisition wise to put the whole thing in place to move on from. Its not pie in the sky either with fda approvals etc and proven but 'youthful' market for collagen based products... which is why im in i believe in the product. I personally think theyre striving to be a nice easy one stop shop aquisition for a big fish... | jacobjohn7 | |
18/11/2015 14:48 | Opinion on results - I will be looking at the obvious figures i.e., revenue and other income and pre-tax losses and also what Stewart White has to say in his statement. It is all very well saying that that the aim is to attain a valuation of £100 Million by 2020, but there comes a point where we need a realistic justification for that valuation. This is what he said in July when the Final Results were announced; Dr Stewart White, Chief Executive Officer of Collagen Solutions, commented: "I believe the Collagen Solutions Group is now an industry-recognised global force in the provision of value-added medical grade collagen biomaterials. The acquisition of Southern Lights Biomaterials cements our position by bringing an impressive customer base, providing surety of supply and commercial experience in the Asian markets. The Group now has a significant number of commercial opportunities to add to its already de-risked business model. Our aim of attaining a valuation of £100 Million by 2020 is certainly closer not only due to M&A activities, but also through the normal course of our business, evidenced by the customer-related announcements we have made in the period. The assessment and plans for commercialisation of our own, and licensed-in IP continues, with the benefit of potential channels to market via an interested and existing customer base and network with which to partner." | doodlebug4 | |
18/11/2015 13:47 | Opinion on results? Think we will move within this trading range till then | jacobjohn7 | |
18/11/2015 12:37 | I agree, I've been holding these for quite some time now and look forward to the results on 1st December. | doodlebug4 | |
18/11/2015 12:27 | I have genuine belief that cos is ripe for being swallowed up as the story unfolds .. | jacobjohn7 | |
18/11/2015 12:23 | Added this morning (44,587) been bouncing about 8-13p for a year.. positive appointment with proven track record... and good buy/top up opportunity as we start an upwards trend | jacobjohn7 | |
03/11/2015 08:42 | RNS Number : 2810E Collagen Solutions PLC 03 November 2015 Collagen Solutions Plc (the "Company" or the "Group") Notice of Half Year Results Analyst Briefing The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, will announce their unaudited interim results for the six months ending 30 September 2015 on Tuesday, 1 December 2015. A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Tuesday 1 December 2015. If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr. | doodlebug4 | |
21/10/2015 12:54 | Half yearly trading statement due in a few weeks time. | doodlebug4 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |